Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

  • Technology appraisal guidance
  • TA779
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance: 1

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators